upon review divergence is seen indicating a change in trend
adx is creating large waves, uptrend may follow
buying pressure is slightly increasing
retesting prior support
may make small gains
The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.
Long term indicators fully support a...
Long term indicators fully support a continuation of the trend.
I could not identify any clear divergence in rsi combined with with price action.
The 20 sma is headed towards a bullish crossover of the 200 sma.
Mac D positive crossover.
The new moon is coming on the 12th, I use the lunar cycle with every trade but it may not be in every description I post. Stock...
(Picture perfect breakout + retest above)
Couple things to point out;
1B authorized, 189M shares Outstanding.
- Already selling in Indonesia, Turkey, Nigeria, Kenya, Bulgaria
-Plans to begin distribution into China, India, Russia, Poland, Hungry
-USA FDA approval is an 18 month+ project
-Product is superior cancer detection; painless, non-invasive with...
Good play on a speculative migraine pain management device.
Around 600 M shares outstanding with low float and virtually no debt.
A small investment in $ADHC could yield exponential returns in a few short years.
Market cap could exceed to over $1B+ with successful FDA and clinical studies then successful marketplace execution.
Over $1 PPS is not unreasonable...
